Abstract
Six hundred million people are threatened by leishmaniasis globally, with 50% of new cases occurring in children. An alternative to antimonial drugs is intravenous liposomal amphotericin B (AmB). Despite promising clinical outcomes, the use of it in low- and middle-income countries where the disease is more prevalent is complex since it often requires inexistent dedicated infrastructure and personnel. Moreover, patients need to attend multiple hospital appointments, often travelling far distances and losing days of work. Here, we report the AmB nanocrystals-loaded dissolving microarray patches as a patient-centric alternative to painful and inconvenient intravenous formulation.Thesis is embargoed until 31st December 2029.
| Date of Award | Dec 2024 |
|---|---|
| Original language | English |
| Awarding Institution |
|
| Supervisor | Alejandro Paredes (Supervisor) & Ryan Donnelly (Supervisor) |
Keywords
- leishmaniasis
- nanocrystal
- microarray patches